

# Anti-CD21 [BU79]

**Catalogue number:** 153224

**Sub-type:**

**Images:**

## Contributor

**Inventor:** Margaret Goodall

**Institute:** University of Birmingham

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-CD21 [BU79]

**Alternate name:** Complement receptor type 2; CR2; complement C3d receptor, C3DR, Epstein-Barr virus receptor

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG1

**Reactivity:** Human

**Selectivity:**

**Host:** Mouse

**Immunogen:** Daudi cell line (B lymphoblast)

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:**  
**Formulation:**  
**Recommended controls:**  
**Bacterial resistance:**  
**Selectable markers:**  
**Additional notes:**

## Target details

**Target:** CD21

**Target alternate names:**

**Target background:** Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

**Molecular weight:**

**Ic50:**

## Applications

**Application:** IHC  
**Application notes:**

## Handling

**Format:** Liquid  
**Concentration:** 0.9-1.1mg/ml  
**Passage number:**  
**Growth medium:**  
**Temperature:**  
**Atmosphere:**  
**Volume:**  
**Storage medium:**  
**Storage buffer:** PBS with 0.02% azide  
**Storage conditions:** -15° C to -25° C  
**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:**

## References

**References:** Leucocyte Typing IV, (1989): edited by W. Knapp, OUP, Oxford. ; Leucocyte Typing V, (1995): edited by S.F. Schlossman, OUP, Oxford. ; Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York.

CancerTools.org